Canaccord raised the firm’s price target on Boston Scientific to $88 from $83 and keeps a Buy rating on the shares. The firm said they reported yet again another beat-and-raise fueled by Farapulse. Separately, the company pushed back the timeline on reading out the US pivotal data from the Acurate neo2 study to ACC in 2025. Given the pause announced and the pushback, they still do not have high expectations for the data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific raises FY24 adjusted EPS view to $2.38-$2.42 from $2.29-$2.34
- Boston Scientific sees Q3 EPS 57c-59c, consensus 57c
- Boston Scientific reports Q2 adjusted EPS 62c, consensus 58c
- Boston Scientific Announces Results for Second Quarter 2024
- Notable companies reporting before tomorrow’s open